Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Ohara Confident of Overcoming Sankyo's Patents on Mevalotin
July 14, 2003
- DIAGNOSTIC NEWS IN BRIEF
July 14, 2003
- ON THE MOVE
July 14, 2003
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
July 14, 2003
- Drug Industry Calls For Budget, Tax Reforms to Strengthen Its Competitiveness
July 14, 2003
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
July 14, 2003
- Versions of Mevalotin, Lipovas Launched by All 4 Top GE Houses
July 14, 2003
- Tsuruha: Sales Increase 14.8% to \116 Bil.
July 14, 2003
- BUSINESS NEWS IN BRIEF
July 14, 2003
- BULLETIN
July 14, 2003
- CORPORATE ROUNDUP NEWS IN BRIEF
July 14, 2003
- Gatiflo Makes Dainippon Revise Mid-term Plan: President Miyatake
July 14, 2003
- 415 GEs, 145 Ingredients Added to NHI Price List
July 14, 2003
- FY2003 Basic Policy on Fiscal, Structural Reform Announced
July 14, 2003
- WORLD NEWS IN BRIEF
July 14, 2003
- Regulatory Reform Council Chairman Satisfied with FY2003 Basic Policy
July 14, 2003
- Mevalotin Retains Top Position, Followed by Gaster, Blopress: Survey
July 14, 2003
- Korosho Council Listens to Industry's Views on Action Plan
July 14, 2003
- Eisai to Beef Up Business Infrastructure in China
July 14, 2003
- 6 Drugs, Recommended for Approval in July
July 14, 2003
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…